Announcement PDF RNS Number : 0274F Genedrive PLC 17 March 2022 genedrive plc ("genedrive" or the "Company") Board appointment genedrive plc (AIM: GDR), the near patient molecular diagnostics company announces the appointment of Russell ("Russ") Shaw as the Group's Chief Financial Officer ("CFO") and a Director of the Company with effect from 7 April 2022. Russell joins genedrive with over 16 years' experience in senior positions in the industrials, technology and business services industries. Prior to joining genedrive, Russell spent 10 years as Finance Director at Driver Group plc, an AIM quoted company providing consultancy services to the engineering and construction industries. Russell has been CFO of several private companies in recent years and currently holds this position at Inflow Consultancy Limited from which he will resign prior to joining the Board of genedrive. Russell is a fellow of the Chartered Institute of Management Accountants. Russell will join the Company as an employee on 23 March 2022 to ensure there is a handover period with the outgoing CFO, Matthew Fowler, who will now be resigning from the Board on 7 April 2022 rather than 19 April 2022 as previously stated. Commenting on the appointment, David Budd, Chief Executive Officer of Genedrive, said: "Russ' experience will allow him to have a positive impact across the Company, both at an operational and strategic level. I am very pleased to have Russ join genedrive and look forward to his contributions and input in the commercial and financial growth of the Company. At the same time, we would like to thank Matthew Fowler for his work and diligence as CFO over the past five years and wish him every success in his next role." Russell Shaw, incoming Chief Financial Officer of Genedrive, said: "I'm excited to be joining genedrive at this stage of development. I am looking forward to working with the Board and the entire operational team to seize opportunities and build on the strengths of the business." The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies: Full name and age: Russell John Shaw (aged 43) Russell Shaw does not currently hold any shares in genedrive plc. Current Directorships or Partnerships: Inflow Consultancy Limited Past Directorships of Partnerships: I4 Technology Group Limited, Edge Worldwide Logistics Limited No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies. For further details please contact: genedrive plc David Budd: CEO +44 (0)161 989 0245 Peel Hunt LLP (Nominated Adviser and Joint Broker) James Steel +44 (0)20 7418 8900 finnCap (Joint Broker) Geoff Nash / Kate Bannatyne / Alice Lane +44 (0)20 7220 0500 Walbrook PR Ltd (Media Relations & Investor Relations) Paul McManus / Anna Dunphy +44 (0)20 7933 8780 or genedrive@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7876 741 001 About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets and a high throughput SARS-CoV-2 assay. The Company has also recently launched a test to help in the prevention of hearing loss caused by certain antibiotics in neonates. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END BOAJFMATMTBBBBT